New irreversible epidermal growth factor receptor inhibitor shows preclinical antitumor activity July 21, 2011
COMP recommends orphan drug status for Nektar Therapeutics' lead oncology agent in ovarian cancer July 19, 2011
Merck & Co.'s new frizzled SMO receptor antagonist MK-5710 has antitumor activity in vivo July 19, 2011
RSS